Listed

Protalix BioTherapeutics, Inc.

PLXNYSECIK 1006281HealthcareFiscal year ends Dec 31

Reports and events: 399 filings

Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.

What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.

Protalix BioTherapeutics, Inc., Reports and events
FiledFormWhat it isAccession number
2023-08-0706:59 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001558370-23-013481
2023-07-1316:41 ET8-K5.07 Shareholder vote results0001558370-23-011868
2023-06-2907:24 ET8-K5.07 Shareholder vote results; 9.01 Financial statements and exhibits0001558370-23-011550
2023-05-3007:23 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001558370-23-010565
2023-05-1817:00 ETDEF 14AProxy statementPeriod 2023-06-280001104659-23-062301
2023-05-1806:57 ET8-K2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits0001558370-23-010154
2023-05-1006:25 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001558370-23-008953
2023-05-0506:56 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001558370-23-008188
2023-05-0416:30 ET10-QQuarterly reportPeriod 2023-03-310001558370-23-008132
2023-05-0407:37 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001558370-23-007978
2023-05-0106:47 ET10-K/AAnnual report, amendedPeriod 2022-12-310001558370-23-007386
2023-02-2706:48 ET8-K1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits0001558370-23-002104
2023-02-2706:45 ET10-KAnnual reportPeriod 2022-12-310001558370-23-002102
2023-02-2706:36 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001558370-23-002100
2023-02-2409:26 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001558370-23-001975
2023-01-0306:57 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001558370-23-000003
2022-12-2716:30 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001558370-22-018990
2022-12-2116:36 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001558370-22-018894
2022-11-1407:07 ET10-QQuarterly reportPeriod 2022-09-300001558370-22-017554
2022-11-1407:03 ET8-K2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits0001558370-22-017549
2022-09-0116:31 ET8-K1.01 Entry into a material agreement; 9.01 Financial statements and exhibits0001558370-22-014127
2022-08-1507:09 ET10-QQuarterly reportPeriod 2022-06-300001558370-22-013560
2022-08-1507:04 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001558370-22-013557
2022-06-3017:10 ET8-K5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 8.01 Other events; 9.01 Financial statements and exhibits0001558370-22-010491
2022-05-2616:39 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001558370-22-009406
2022-05-1607:09 ET10-QQuarterly reportPeriod 2022-03-310001558370-22-008847
2022-05-1607:00 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001558370-22-008843
2022-05-0206:24 ET8-K1.01 Entry into a material agreement; 9.01 Financial statements and exhibits0001558370-22-006566
2022-04-2916:36 ETDEF 14AProxy statementPeriod 2022-06-300001104659-22-053664
2022-04-0406:59 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001558370-22-005043
2022-03-3107:12 ET10-KAnnual reportPeriod 2021-12-310001558370-22-004823
2022-03-3107:01 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001558370-22-004821
2022-02-2409:19 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001558370-22-001858
2021-12-2206:55 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001558370-21-016986
2021-11-2416:30 ET8-K5.07 Shareholder vote results0001558370-21-016327
2021-11-1507:19 ET10-QQuarterly reportPeriod 2021-09-300001558370-21-015862
2021-11-1507:06 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001558370-21-015857
2021-10-1206:03 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001558370-21-013109
2021-09-3016:30 ETDEF 14AProxy statementPeriod 2021-11-240001558370-21-012901
2021-08-2607:16 ET8-K1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits0001558370-21-012078
2021-08-1607:17 ET10-QQuarterly reportPeriod 2021-06-300001558370-21-011752
2021-08-1607:08 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001558370-21-011750
2021-08-1307:05 ET8-K1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits0001558370-21-011566
2021-07-0716:31 ET8-K5.07 Shareholder vote results0001558370-21-008801
2021-07-0217:05 ET8-K1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits0001104659-21-088982
2021-06-3017:23 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001558370-21-008725
2021-06-0416:30 ETDEF 14AProxy statementPeriod 2021-07-070001558370-21-008019
2021-06-0207:02 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001558370-21-007920
2021-05-1407:04 ET10-QQuarterly reportPeriod 2021-03-310001558370-21-007157
2021-05-1406:56 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001558370-21-007154

Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Nov 10, 2026, 16:48 ET. Listed shows no prices and gives no investment advice.